NEWSLETTER: INTERREG. PROJECT ”HERINNERINGEN” (”MEMORIES”), issue 3

1. Optimization of in vitro exposure regimes to assure risk factor induced adverse effects in the absence of cytotoxicity.
2. Hitting the road.

Newsletter_072019


ToxGenSolutions BV

Erwin L Roggen (CEO): More than 25 years of industrial experience (including 15 years as a manager) in the development, implementation and use of animal-free methods; Self-employed since 2013 (www.3rsmc-aps.com) with the mission to valorise promising animal-free methods; Founder and co-owner (2011) of the listed company SenzaGen AB (Lund, Sweden) (www.senzagen.com), specialized in cell-based identification methods for allergens. profile: http://www.linkedin.com/profile/view?id=23021602&trk=tab_pro